|Dr. Gary S. Jacob Ph.D.||Chairman, Chief Exec. Officer & Pres||844.01k||N/A||70|
|Dr. Kunwar Shailubhai Ph.D., M.B.A.||Chief Scientific Officer and Exec. VP||524.29k||N/A||59|
|Dr. Patrick H. Griffin M.D., FACP||Exec. VP & Chief Medical Officer||607.65k||N/A||62|
|Mr. Troy Hamilton PharmD||Exec. VP & Chief Commercial Officer||567.5k||N/A||45|
|Mr. Bernard F. Denoyer CPA, M.B.A.||Exec. Officer||331.19k||N/A||69|
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin analog that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.
Synergy Pharmaceuticals Inc.’s ISS Governance QualityScore as of June 2, 2017 is 8. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 2; Compensation: 10.